Merck KGaA: wins EU approval for multiple sclerosis drug.
(CercleFinance.com) - Germany's Merck said on Friday that it has received EU approval for Mavenclad, a treatment for highly active relapsing multiple sclerosis.
The approval applies to all 28 countries of the European Union, in addition to Norway, Liechtenstein and Iceland.
The drugmaker said Mavenclad is the first oral treatment to improve key measures of disease activity in patients with multiple sclerosis, a disease that affects over 700,000 people across Europe.
Merck now plans additional filings for regulatory approval in other countries, including the United States.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The approval applies to all 28 countries of the European Union, in addition to Norway, Liechtenstein and Iceland.
The drugmaker said Mavenclad is the first oral treatment to improve key measures of disease activity in patients with multiple sclerosis, a disease that affects over 700,000 people across Europe.
Merck now plans additional filings for regulatory approval in other countries, including the United States.
Copyright (c) 2017 CercleFinance.com. All rights reserved.